Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$118.13

0.86 (0.73%)

, ABBV

AbbVie

$63.07

0.25 (0.40%)

15:04
10/02/16
10/02
15:04
10/02/16
15:04

Janssen reports Phase 3 data on guselkumab in psoriasis, says shows superiority

Johnson & Johnson's (JNJ) Janssen announced findings from the first of three pivotal Phase 3 studies evaluating guselkumab, an anti-interleukin-23 monoclonal antibody in development for the treatment of adults with moderate to severe plaque psoriasis. Data from the VOYAGE 1 trial showed significantly higher proportions of patients receiving guselkumab achieved cleared/minimal disease compared with patients receiving placebo, as defined by at least a 90 percent improvement in the Psoriasis Area Severity Index and an Investigator's Global Assessment score of cleared or minimal disease at week 16, the study co-primary endpoints. The VOYAGE 1 trial also included an active comparator arm evaluating guselkumab versus AbbVie's (ABBV) Humira, and showed the superiority of guselkumab across major study endpoints and through 48 weeks of treatment. These data were presented for the first time at the European Academy of Dermatology and Venereology Congress. Specifically, in VOYAGE 1, the co-primary endpoints were met at week 16, with 85.1 percent of patients receiving guselkumab 100 mg at weeks 0 and 4 and then every eight weeks achieving cleared or minimal disease compared with 6.9 percent of patients receiving placebo. Nearly three-quarters of patients receiving guselkumab -- 73.3 percent -- achieved a PASI 90 response, or near complete skin clearance, compared with 2.9 percent of patients receiving placebo. All major secondary endpoints in VOYAGE 1 achieved statistical significance in comparisons of guselkumab versus adalimumab administered subcutaneously at weeks 0, 1 and then 40 mg every other week. At week 16, following three injections of guselkumab and ten injections of adalimumab, significantly higher proportions of patients receiving guselkumab achieved IGA 0/1 and PASI 90 -- 85.1 percent and 73.3 percent, respectively -- compared with patients receiving adalimumab -- 65.9 percent and 49.7 percent, respectively. At week 24, the proportion of patients who achieved a PASI 90 response was significantly higher in the guselkumab group compared with the adalimumab group -- 80.2 percent vs. 53.0 percent, respectively. Higher levels of skin clearance among the guselkumab group continued through weeks 24 and 48, with significantly more patients receiving guselkumab achieving IGA 0/1 and PASI 90, as well as measures of full skin clearance compared with adalimumab. The Dermatology Life Quality Index assessed the impact of disease and disease improvement following therapy on study participants' quality of life. At week 24, a score of 0/1, indicating no impact of psoriasis on health-related quality of life, was achieved by 60.9 percent of patients receiving guselkumab compared with 39.5 percent of patients receiving adalimumab. Guselkumab-treated patients also showed substantial improvement at week 48 with 62.5 percent scoring a DLQI of 0/1 compared with 38.9 percent of adalimumab-treated patients. Through week 16 of the study, the placebo-controlled period, serious AEs were reported in 1.7 percent of patients receiving placebo, 2.4 percent of patients receiving guselkumab and 1.8 percent of patients receiving adalimumab. Through week 48 of the study, the proportions of patients reporting at least one AE were comparable between guselkumab -- 73.9 percent -- and adalimumab -- 74.5 percent; the proportions of patients reporting serious AEs were also similar for guselkumab -- 4.9 percent -- and adalimumab -- 4.5 percent. Serious infections occurred in two patients receiving guselkumab and three patients receiving adalimumab. Through week 48, there was one myocardial infarction in each of the guselkumab and adalimumab treatment groups, and two solid malignancies -- one prostate and one breast cancer -- were reported in patients receiving guselkumab.

JNJ

Johnson & Johnson

$118.13

0.86 (0.73%)

ABBV

AbbVie

$63.07

0.25 (0.40%)

  • 04

    Oct

  • 07

    Oct

  • 18

    Oct

  • 06

    Nov

JNJ Johnson & Johnson
$118.13

0.86 (0.73%)

08/18/16
UBSW
08/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson remains a top large cap pick, says UBS
UBS analyst Matt Miksic said Johnson & Johnson remains a top large cap diversified pick for the year. The analyst said yesterday's court ruling that invalidated the company's Remicade patent was expected and could delay the Q4 biosimilar launch but its robust pharma pipeline remains under-appreciated and should make up the difference. He said he continues to see further clarity regarding potential U.S. biosimilar competition for Remicade as positive for the stock. Miksic reiterated his Buy rating and $137 price target on Johnson & Johnson shares.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
08/24/16
JEFF
08/24/16
NO CHANGE
Target $210
JEFF
Buy
Cooper Companies estimates raised at Jefferies after doctor survey
Jefferies analyst Anthony Petrone reports that the firm's survey of 52 new optometry practices suggest continued gains in dailies and stable share in monthlies for Cooper Companies (COO) and that Johnson & Johnson's (JNJ) Acuvue Vita is off to slow start. Based on the survey results, and a "significant" foreign exchange tailwind, Petrone raised his estimates for Cooper and increased his price target on the shares to $210 from $190. The firm has a Buy rating on Cooper shares.
ABBV AbbVie
$63.07

0.25 (0.40%)

09/08/16
JPMS
09/08/16
DOWNGRADE
Target $73
JPMS
Neutral
AbbVie downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chris Schott downgraded AbbVie (ABBV) to Neutral citing the stock's 10% rally year-to-date and limited near-term catalysts. AbbVie's profile is now better reflected at current valuation levels, Schott tells investors in a research note. He lowered his price target for the shares to $73 from $75. The analyst coupled the downgrade with an upgrade this morning of Eli Lilly (LLY) to Overweight.
09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/01/16
RAJA
09/01/16
INITIATION
Target $82
RAJA
Outperform
AbbVie initiated with an Outperform at Raymond James
Target $82.
07/14/16
JEFF
07/14/16
NO CHANGE
JEFF
AbbVie remains Jefferies' Top Pick in Global Pharma
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his firm's Top Pick in Global Pharmaceuticals, followed by Eli Lilly (LLY), Novartis (NVS), GlaxoSmithKline (GSK) and Zoetis (ZTS). The analyst this morning upgraded GSK to Buy from Hold. Holford also remains positive on Roche (RHHBY), Abbott (ABT) and Pfizer (PFE). The analyst's least preferred names are Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Merck (MRK). The Q2 earnings season offers "few clear beat and raise" stories and looks weakest for AstraZeneca (AZN) against preliminary consensus, Holford tells investors in a pre-earnings research note.

TODAY'S FREE FLY STORIES

NUE

Nucor

$62.83

1.97 (3.24%)

15:46
02/27/17
02/27
15:46
02/27/17
15:46
Options
Nucor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKA

Roka Bioscience

$4.26

-0.18 (-4.05%)

15:44
02/27/17
02/27
15:44
02/27/17
15:44
Conference/Events
Roka Bioscience to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 29

    Mar

TESS

TESSCO

$14.05

-0.3 (-2.09%)

15:43
02/27/17
02/27
15:43
02/27/17
15:43
Hot Stocks
TESSCO signs deal with GEAR4 as exclusive U.S. distributor »

TESSCO Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LJPC

La Jolla

$19.87

1.65 (9.06%)

15:42
02/27/17
02/27
15:42
02/27/17
15:42
Recommendations
La Jolla analyst commentary  »

La Jolla price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 19

    Mar

CUR

Neuralstem

$3.86

0.16 (4.32%)

15:36
02/27/17
02/27
15:36
02/27/17
15:36
Hot Stocks
Breaking Hot Stocks news story on Neuralstem »

Tianjin Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WUBA

58.com

$32.46

0.49 (1.53%)

15:35
02/27/17
02/27
15:35
02/27/17
15:35
Options
58.com options imply 10.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NURO

NeuroMetrix

$0.63

-0.0317 (-4.79%)

15:35
02/27/17
02/27
15:35
02/27/17
15:35
Conference/Events
NeuroMetrix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CGI

Celadon Group

$8.55

0.45 (5.56%)

, USAK

USA Truck

$9.00

0.14 (1.58%)

15:33
02/27/17
02/27
15:33
02/27/17
15:33
Hot Stocks
Celadon, USA Truck called best M&A targets as truckers seen consolidating »

Stephens argued that amid…

CGI

Celadon Group

$8.55

0.45 (5.56%)

USAK

USA Truck

$9.00

0.14 (1.58%)

HTLD

Heartland Express

$20.64

0.2 (0.98%)

KNX

Knight Transportation

$32.70

0.55 (1.71%)

SWFT

Swift Transportation

$22.09

0.35 (1.61%)

CVTI

Covenant Transportation

$20.06

0.05 (0.25%)

MRTN

Marten Transport

WERN

Werner

$27.80

0.45 (1.65%)

XPO

XPO Logistics

$51.41

1.01 (2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 02

    May

GLD

SPDR Gold Trust

$119.45

-0.25 (-0.21%)

15:32
02/27/17
02/27
15:32
02/27/17
15:32
Options
Aggressive short-term call spread in the SPDR Gold Fund »

Aggressive short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGY

Stone Energy

$6.73

0.15 (2.28%)

, EQT

EQT Corporation

$60.73

0.785 (1.31%)

15:31
02/27/17
02/27
15:31
02/27/17
15:31
Hot Stocks
Stone Energy announces close of sale of Appalachia properties »

Stone Energy (SGY)…

SGY

Stone Energy

$6.73

0.15 (2.28%)

EQT

EQT Corporation

$60.73

0.785 (1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXEL

Exelixis

$21.69

-0.05 (-0.23%)

15:20
02/27/17
02/27
15:20
02/27/17
15:20
Options
Exelixis options imply 12.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

$NSD

NASDAQ Market Internals

15:17
02/27/17
02/27
15:17
02/27/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
02/27/17
02/27
15:16
02/27/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$29.94

-0.25 (-0.83%)

15:14
02/27/17
02/27
15:14
02/27/17
15:14
Periodicals
GE sales process for Industrial Solutions may start in March, Bloomberg says »

Amid its continuing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

VIP

VimpelCom

$4.30

-0.04 (-0.92%)

15:11
02/27/17
02/27
15:11
02/27/17
15:11
Options
Higher option volume in Vimpel driven by poste-earnings puts »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAC

Marriott Vacations

$96.51

-2.39 (-2.42%)

15:09
02/27/17
02/27
15:09
02/27/17
15:09
Conference/Events
Marriott Vacations management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TGT

Target

$66.95

0.435 (0.65%)

, AZO

AutoZone

$734.44

1.685 (0.23%)

15:06
02/27/17
02/27
15:06
02/27/17
15:06
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TGT

Target

$66.95

0.435 (0.65%)

AZO

AutoZone

$734.44

1.685 (0.23%)

DPZ

Domino's Pizza

$185.90

-0.378 (-0.20%)

VRX

Valeant

$16.73

0.5499 (3.40%)

PAH

Platform Specialty Products

$13.19

0.14 (1.07%)

ENDP

Endo

$13.15

-0.24 (-1.79%)

DDD

3D Systems

$17.04

0.55 (3.34%)

SEAS

SeaWorld

$18.66

0.035 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

PCLN

Priceline

$1,631.62

-5.64 (-0.34%)

, WDAY

Workday

$90.92

1.26 (1.41%)

15:05
02/27/17
02/27
15:05
02/27/17
15:05
Earnings
Notable companies reporting after market close »

Notable companies…

PCLN

Priceline

$1,631.62

-5.64 (-0.34%)

WDAY

Workday

$90.92

1.26 (1.41%)

PRGO

Perrigo

$84.39

-0.04 (-0.05%)

ALB

Albemarle

$92.74

-0.19 (-0.20%)

EXEL

Exelixis

$21.69

-0.05 (-0.23%)

RSPP

RSP Permian

$40.77

0.88 (2.21%)

FTR

Frontier Communications

$3.37

-0.02 (-0.59%)

CST

CST Brands

$48.37

0.02 (0.04%)

THC

Tenet

$22.36

0.365 (1.66%)

HTZ

Hertz

$19.86

-0.11 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 13

    Mar

  • 14

    Mar

  • 16

    Mar

  • 20

    Mar

  • 21

    Mar

HTZ

Hertz

$19.87

-0.105 (-0.53%)

15:05
02/27/17
02/27
15:05
02/27/17
15:05
Options
Hertz options imply 18.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

15:00
02/27/17
02/27
15:00
02/27/17
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

MNK

Mallinckrodt

$54.42

1.04 (1.95%)

14:57
02/27/17
02/27
14:57
02/27/17
14:57
Conference/Events
Mallinckrodt management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 03

    Mar

INCY

Incyte

$131.21

9.26 (7.59%)

, SE

Acquired by ENB

14:55
02/27/17
02/27
14:55
02/27/17
14:55
Hot Stocks
Incyte to replace Spectra Energy in S&P 500 as of 2/28 open »

Spectra Energy (SE) is…

INCY

Incyte

$131.21

9.26 (7.59%)

SE

Acquired by ENB

ENB

Enbridge

$42.05

0.705 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 14

    Mar

  • 01

    Apr

  • 19

    Apr

DDS

Dillard's

$56.99

-0.01 (-0.02%)

, ISIL

Intersil

14:55
02/27/17
02/27
14:55
02/27/17
14:55
Hot Stocks
Dillard's to replace Intersil in S&P 400 as of 2/28 open »

Renesas Electronics Corp.…

DDS

Dillard's

$56.99

-0.01 (-0.02%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRK

WestRock

$53.69

0.26 (0.49%)

14:54
02/27/17
02/27
14:54
02/27/17
14:54
Conference/Events
WestRock management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

GIG

GigPeak

$3.10

0.03 (0.98%)

14:52
02/27/17
02/27
14:52
02/27/17
14:52
Hot Stocks
Gardner Lewis reports new 8.6% stake in GigPeak »

Shares of GigPeak spiked…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

  • 05

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.